Camp4 Therapeutics (CAMP) EBIT (2023 - 2026)

Camp4 Therapeutics has reported EBIT for 4 years, with the latest figure at -$13.1 million in Q1 2026.

• Quarterly EBIT changed 0.22% year-over-year to -$13.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$52.5 million (up 1.47% YoY) and the FY2025 annual result came in at -$52.6 million, up 1.0% from the prior year.
• EBIT slipped to -$13.1 million in Q1 2026 per CAMP's latest filing, from -$12.8 million in the prior quarter.
• Over five years, EBIT peaked at -$12.3 million in Q3 2023 and troughed at -$14.0 million in Q4 2024.
• A 4-year average of -$13.1 million and a median of -$13.1 million in 2026 frame the typical range for EBIT.
• The sharpest annual moves came in 2024 and 2025: EBIT fell 9.55% in 2024, then grew 8.96% in 2025.
• Over 4 years, EBIT stood at -$13.5 million in 2023, then decreased by 4.14% to -$14.0 million in 2024, then increased by 8.96% to -$12.8 million in 2025, then dropped by 2.31% to -$13.1 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$13.1 million, -$12.8 million, and -$13.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.